MYB-activated models for testing therapeutic agents in adenoid cystic carcinoma.

ABSTRACT:

Objective

There are no effective systemic therapies for adenoid cystic cancer (ACC) and lack of tumor lines and mouse models have hindered drug development.We aim to develop MYB-activated models for testing new therapeutic agents.

Materials and methods

We studied new ACC patient-derived xenograft (PDX) models and generated a matched cell line from one patient. In addition, we generated a genetically-engineered MYB-NFIB mouse model (GEMM) that was crossed with Ink4a^+/-/Arf^+/- mice to study tumor spectrum and obtain tumor lines. Using human and murine ACC-like tumor lines, we analyzed MYB expression by RNA-Seq and immunoblot and tested efficacy of new MYB inhibitors.

Results

We detected MYB-NFIB transcripts in both UFH1 and UF

SUBMITTER: Jiang Y 

PROVIDER: S-EPMC7184536 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature